[Form 4] Rocket Pharmaceuticals, Inc. Insider Trading Activity
Rocket Pharmaceuticals insider Martin Wilson sold 12,109 shares of common stock on 08/14/2025 at $3.019 per share to satisfy tax withholding arising from the vesting of restricted stock units (RSUs). After the sale, the reporting person beneficially owned 137,054 shares. The Form 4 lists Mr. Wilson as General Counsel and an officer of the issuer and is signed on 08/18/2025.
Il dirigente di Rocket Pharmaceuticals, Martin Wilson, ha venduto 12.109 azioni ordinarie il 14/08/2025 a 3,019$ per azione per coprire le imposte dovute alla maturazione di restricted stock units (RSU). Dopo la vendita, la persona segnalante possedeva di fatto 137.054 azioni. Il Modulo 4 indica che il Sig. Wilson 猫 General Counsel e dirigente dell'emittente ed 猫 firmato il 18/08/2025.
El directivo de Rocket Pharmaceuticals, Martin Wilson, vendi贸 12.109 acciones ordinarias el 14/08/2025 a 3,019$ por acci贸n para cubrir la retenci贸n fiscal derivada del vencimiento de unidades de acciones restringidas (RSU). Tras la venta, la persona declarada pose铆a beneficiariamente 137.054 acciones. El Formulario 4 indica que el Sr. Wilson es Asesor General y funcionario del emisor y est谩 firmado el 18/08/2025.
搿滌紦 韺岆鞀堩嫲旎姢鞚� 鞛勳洂 毵堩嫶 鞙岇姩鞚� 2025雲� 8鞗� 14鞚� 鞝滍暅欤检嫕雼渼(RSU) 旆摑鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暣 氤错喌欤� 12,109欤茧ゼ 欤茧嫻 3.019雼煬鞐� 毵る弰頄堨姷雼堧嫟. 毵る弰 頉� 鞁犼碃鞚胳潃 鞁れ鞝侅溂搿� 137,054欤茧ゼ 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞏戩嫕 4鞐愲姅 鞙岇姩 鞌皜 氚滍枆須岇偓鞚� 氩曤齑濌磩(General Counsel) 瓴� 鞛勳洂鞙茧 旮办灛霅橃柎 鞛堨溂氅� 2025雲� 8鞗� 18鞚� 靹滊獏霅橃棃鞀惦媹雼�.
Le cadre de Rocket Pharmaceuticals, Martin Wilson, a vendu 12 109 actions ordinaires le 14/08/2025 au prix de 3,019 $ par action afin de couvrir la retenue d'imp么t li茅e 脿 la lev茅e d'unit茅s d'actions restreintes (RSU). Apr猫s la vente, la personne d茅clar茅e d茅tenait b茅n茅volement 137 054 actions. Le formulaire 4 indique que M. Wilson est General Counsel et dirigeant de l'茅metteur et porte la signature du 18/08/2025.
Der Insider von Rocket Pharmaceuticals, Martin Wilson, verkaufte am 14.08.2025 insgesamt 12.109 Stammaktien zu je 3,019$ zur Begleichung der Steuerabz眉ge, die durch das Vesting von Restricted Stock Units (RSUs) entstanden sind. Nach dem Verkauf verf眉gte die meldepflichtige Person wirtschaftlich 眉ber 137.054 Aktien. In Formular 4 wird Herr Wilson als General Counsel und leitender Angestellter des Emittenten aufgef眉hrt; das Formular ist am 18.08.2025 unterzeichnet.
- Transaction disclosed as tax-withholding related to RSU vesting, indicating the sale was a routine, plan-driven disposition.
- Form 4 provides post-transaction beneficial ownership (137,054 shares) and includes the reporting person's title (General Counsel), supporting transparency.
- Reporting person disposed of 12,109 shares, reducing direct ownership, which some investors may note even though it was for tax withholding.
Insights
TL;DR: Insider sale was a tax-withholding sale tied to RSU vesting and left the officer with 137,054 shares; impact appears routine.
The Form 4 discloses a sale of 12,109 common shares at $3.019 on 08/14/2025 explicitly to pay tax withholding for vested RSUs that convert one-for-one to common stock. The transaction reduces reported direct beneficial ownership to 137,054 shares. This is a standard, non-discretionary disposition related to compensation settlement rather than a discretionary open-market sale for liquidity. Filing appears complete and timely based on the signature date provided.
TL;DR: The disclosure aligns with Rule 16 reporting norms; sale was for tax obligations tied to equity compensation.
The reporting person is identified as General Counsel and filed a Form 4 recording a Section 16 transaction. The explanation clarifies the sale was to satisfy tax withholding on RSU vesting, which is a common plan-related action. The Form 4 includes the pre- and post-transaction beneficial ownership and the signature, meeting basic governance disclosure expectations. No additional governance issues are disclosed in this filing.
Il dirigente di Rocket Pharmaceuticals, Martin Wilson, ha venduto 12.109 azioni ordinarie il 14/08/2025 a 3,019$ per azione per coprire le imposte dovute alla maturazione di restricted stock units (RSU). Dopo la vendita, la persona segnalante possedeva di fatto 137.054 azioni. Il Modulo 4 indica che il Sig. Wilson 猫 General Counsel e dirigente dell'emittente ed 猫 firmato il 18/08/2025.
El directivo de Rocket Pharmaceuticals, Martin Wilson, vendi贸 12.109 acciones ordinarias el 14/08/2025 a 3,019$ por acci贸n para cubrir la retenci贸n fiscal derivada del vencimiento de unidades de acciones restringidas (RSU). Tras la venta, la persona declarada pose铆a beneficiariamente 137.054 acciones. El Formulario 4 indica que el Sr. Wilson es Asesor General y funcionario del emisor y est谩 firmado el 18/08/2025.
搿滌紦 韺岆鞀堩嫲旎姢鞚� 鞛勳洂 毵堩嫶 鞙岇姩鞚� 2025雲� 8鞗� 14鞚� 鞝滍暅欤检嫕雼渼(RSU) 旆摑鞐� 霐半ジ 靹戈笀 鞗愳矞歆曥垬毳� 於╇嫻頃橁赴 鞙勴暣 氤错喌欤� 12,109欤茧ゼ 欤茧嫻 3.019雼煬鞐� 毵る弰頄堨姷雼堧嫟. 毵る弰 頉� 鞁犼碃鞚胳潃 鞁れ鞝侅溂搿� 137,054欤茧ゼ 氤挫湢頃橁碃 鞛堨棃鞀惦媹雼�. 鞏戩嫕 4鞐愲姅 鞙岇姩 鞌皜 氚滍枆須岇偓鞚� 氩曤齑濌磩(General Counsel) 瓴� 鞛勳洂鞙茧 旮办灛霅橃柎 鞛堨溂氅� 2025雲� 8鞗� 18鞚� 靹滊獏霅橃棃鞀惦媹雼�.
Le cadre de Rocket Pharmaceuticals, Martin Wilson, a vendu 12 109 actions ordinaires le 14/08/2025 au prix de 3,019 $ par action afin de couvrir la retenue d'imp么t li茅e 脿 la lev茅e d'unit茅s d'actions restreintes (RSU). Apr猫s la vente, la personne d茅clar茅e d茅tenait b茅n茅volement 137 054 actions. Le formulaire 4 indique que M. Wilson est General Counsel et dirigeant de l'茅metteur et porte la signature du 18/08/2025.
Der Insider von Rocket Pharmaceuticals, Martin Wilson, verkaufte am 14.08.2025 insgesamt 12.109 Stammaktien zu je 3,019$ zur Begleichung der Steuerabz眉ge, die durch das Vesting von Restricted Stock Units (RSUs) entstanden sind. Nach dem Verkauf verf眉gte die meldepflichtige Person wirtschaftlich 眉ber 137.054 Aktien. In Formular 4 wird Herr Wilson als General Counsel und leitender Angestellter des Emittenten aufgef眉hrt; das Formular ist am 18.08.2025 unterzeichnet.
FAQ
What did Rocket Pharmaceuticals insider Martin Wilson report on Form 4?
Why were the shares sold according to the filing?
How many Rocket Pharmaceuticals shares does the reporting person own after the transaction?
What is the reporting person's role at Rocket Pharmaceuticals (RCKT)?
When was the Form 4 signed?
